Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

A letter from several Democratic Senators urged Trump to use his deal-making skills to “flat out reject any request to end ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduc ...

The startups are the fourth and fifth drugmakers to file for initial public offerings since late December — the most notable ...

After hitting a regulatory roadblock in 2022, Sanofi’s consumer healthcare business Opella has secured the FDA’s blessing to ...

Progressive has maintained its dominant position as the most-aired radio advertiser nationwide for the week of January 13-19, ...

We recently compiled a list of the 10 Best High-Yield Dividend Stocks To Invest In. In this article, we are going to take a ...

Pharmaceutical stocks can bring an element of safety to your portfolio. Why is this the case? These companies make drugs ...

Bierman, chief market technician at Theo Trade and an adjunct professor of finance at Loyola University Chicago, says investors will be dealing with greater stock-market volatility and uncertainty ...

Patients in the Veritac-2 study were randomized to receive a standard estrogen blocker called fulvestrant, or Arvinas' ...

Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...

Many of the most devastating infectious diseases are caused by RNA viruses and Model Medicines is working on one compound to ...